FDA approves capmatinib, first targeted therapy for metastatic non-small cell lung cancer with specific mutation (METex14).

Capmatinib is an oral therapy that specifically targets tumours with an abnormal mesenchymal-epithelial transition gene leading to MET exon 14 skipping (METex14). Trials showed overall response rate of 68% in treatment naïve and 41% in previously-treated patients.


US Food and Drug Administration